Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Nortek Inc (NTK): Gates Capital Management Increases its Stake to Over 20%

Jeffrey GatesGates Capital Management is strengthening its stake in Nortek Inc (NASDAQ:NTK). According to a recent filing with the Securities and Exchange Commission (SEC), the fund purchased over 150,000 shares to take its total holding in the company to over 3.22 million shares. With this purchase, Gates Capital Management now owns over 20% of all common stock of Nortek Inc (NASDAQ:NTK), though the stake is passive by nature.


Gates is placing a big bet on Nortek Inc (NASDAQ:NTK), which currently constitutes around 8% of the fund’s equity portfolio. The fund initiated its position in Nortek Inc (NASDAQ:NTK) during the last quarter of 2011, since then the stock is up over 250%. Gates Capital Management is an event-driven fund that tries to find ‘dislocation event’ at public companies which are creating substantial value and cash flow. Other major holdings of the fund include Darling Ingredients Inc (NYSE:DAR), shares of which are down almost 20% year over year, but up more than 130% in the last five years, and Rockwood Holdings, Inc. (NYSE:ROC), which is up over 10% year over year.

Joshua Friedman and Mitchell Julis’ Canyon Capital Advisors is another major investor in the company, which as of June 30, 2014, owns over 1.2 million shares. Edward A. Mule’s Silver Point Capital increased its stake in the company by 214% to 550,000 shares during the second quarter.

In a recent filing with the SEC, Nortek Inc (NASDAQ:NTK) mentioned that for the fiscal year ending on December 31, 2014 it expects net sales to be in the range of $2.45 – $2.5 billion and adjusted EBITDA to be in the range of $265- $273 million. For the last fiscal year, the company had reported adjusted EBITDA of around $129 million and revenue of $2.288 billion. The company declared a negative EPS of $2.97 for the second quarter of 2014, versus an EPS of $0.73 in the same period last year. The company trades at 18 times its forward earnings.

On October 8, Nortek Inc (NASDAQ:NTK) announced acquisition of HVAC distribution business of privately owned Phoenix Wholesale, Inc. The company expects this transaction to generate incremental revenue in the range of $15 million to $20 million in the next 12 months. Most analysts and brokerages are optimistic about the stock. It has an average recommendation ‘Overweight’ and an average price target of around $91.5. Imperial Capital has recently initiated coverage on Nortek Inc (NASDAQ:NTK), setting ‘In-line’ rating.

Academic research on trading activity by hedge funds has shown that when they continuously increase their stake it a company, it outperforms its peers by a wide margin in the near future. Though regular investors can’t boast of the resources at disposal of hedge funds, by following the activity of proven hedge funds, they can surely emulate the returns generated by these funds and that too at a much cheaper cost.

Disclosure: None

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.